THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA

神经母细胞瘤炎症的引发和调节

基本信息

  • 批准号:
    9927590
  • 负责人:
  • 金额:
    $ 24.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2021-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The long-term goal of our research is to provide the mechanistic basis for the development of an effective immunotherapy for cancer using the natural and engineered properties of V24-invariant Natural Killer T cells (iNKTs). In the course of the mechanistic studies supported by this grant we have found that iNKTs traffic toward NB in response to tumor-derived chemokines and mediate anti-tumor activity indirectly via targeting of tumor-associated macrophages (TAMs). We also demonstrated that TAMs infiltrate primary tumors in a subset of NB patients and the presence of M2-like TAMs is associated with a novel inflammatory signature that serves as an independent prognostic factor of poor outcome. However, the mechanisms responsible for the initiation and regulation of tumor-supporting inflammation in NB are unknown and will be addressed in the renewal application. In the search for the molecular triggers of an inflammatory response in NB, we found that a subset of NB cells in all examined human and murine cell lines, as well as primary human and transgenic murine tumors, expresses a transmembrane form of TNFα (tmTNFα). Recent reports suggest that unlike soluble (s)TNFα, tmTNFα preferentially activates TNFR2 in monocytic cells and promotes their M2-like differentiation and suppressive activity. Our preliminary data suggest that iNKTs may counteract this process via selective recognition of M2-polarized macrophages. Moreover, crossing NBL-Tag transgenic mice, which spontaneously develop NB, with iNKT-cell deficient animals resulted in an acceleration of tumor growth and an increase of TAM frequency. However, TAMs eventually evade iNKT-cell control, and the evasion is associated with tumor progression. Therefore, we hypothesize that i) tmTNFα-expressing NB cells initiate tumor-supportive inflammation via activation of M2-like TAMs; ii) iNKTs regulate tumor-induced inflammation and indirectly inhibit tumor growth via killing or reprograming of M2-like TAMs; iii) TAMs neutralize iNKTs and enable tumor escape. The following specific aims will test these hypotheses: 1) to examine and therapeutically explore the mechanism by which tmTNFα in NB cells trigger tumor-supportive inflammation; 2) to examine and therapeutically explore the mechanism of reciprocal inhibition between iNKTs and TAMs in the tumor microenvironment. We will use genetic loss of function and gain of function approaches to study the role of NB-derived TNFα isoforms in the activation and functional differentiation of macrophages using in vitro systems with human cells, a syngeneic NB model in mice, and primary tumor specimens from NB patients. To study reciprocal interactions between iNKT and TAMs we recently characterized transgenic NB models with and without genetic deficiency of iNKTs or all NKTs. Finally, we will test whether therapeutic targeting of TAMs maximizes the anti-tumor potential of iNKT-cell immunotherapy for NB. The results are expected to reveal novel mechanisms that govern the initiation and regulation of inflammation in NB and to help identify cellular and molecular targets for the development of effective immunotherapy for NB and other types of cancer.
 描述(由申请人提供):我们研究的长期目标是为开发一种有效的癌症免疫疗法提供机制基础,这种免疫疗法使用V β 24不变的自然杀伤T细胞(iNKT)的天然和工程特性。过程中 在该基金支持的机制研究中,我们发现iNKT响应于肿瘤衍生的趋化因子而向NB运输,并通过靶向肿瘤相关巨噬细胞(TAM)间接介导抗肿瘤活性。我们还证明了TAM浸润NB患者亚组中的原发性肿瘤,并且M2样TAM的存在与新的炎症特征相关,该炎症特征作为预后不良的独立预后因素。然而,负责NB中肿瘤支持性炎症的启动和调节的机制尚不清楚,将在更新申请中解决。在寻找NB中炎症反应的分子触发因子时,我们发现所有检查的人和鼠细胞系以及原发性人和转基因鼠肿瘤中的NB细胞亚群表达TNFα(tmTNFα)的跨膜形式。最近的报道表明,与可溶性TNFα不同,tmTNFα优先激活单核细胞中的TNFR 2,并促进其M2样分化和抑制活性。我们的初步数据表明,iNKT可能通过选择性识别M2极化的巨噬细胞来抵消这一过程。此外,将自发发展NB的NBL-Tag转基因小鼠与iNKT细胞缺陷动物杂交导致肿瘤生长加速和TAM频率增加。然而,TAM最终逃避iNKT细胞控制,并且这种逃避与肿瘤进展相关。因此,我们假设i)表达tmTNFα的NB细胞通过激活M2样TAM引发肿瘤支持性炎症; ii)iNKT通过杀死或重编程M2样TAM调节肿瘤诱导的炎症并间接抑制肿瘤生长; iii)TAM中和iNKT并使肿瘤逃逸。以下具体目标将检验这些假设:1)检查和治疗性探索NB细胞中tmTNFα触发肿瘤支持性炎症的机制; 2)检查和治疗性探索肿瘤微环境中iNKT和TAM之间相互抑制的机制。我们将使用人细胞体外系统、小鼠同基因NB模型和NB患者原发性肿瘤标本,采用遗传功能丧失和功能获得方法研究NB衍生的TNFα亚型在巨噬细胞活化和功能分化中的作用。为了研究iNKT和TAM之间的相互作用,我们最近表征了具有和不具有iNKT或所有NKT的遗传缺陷的转基因NB模型。最后,我们将测试TAM的治疗靶向是否最大化NB的iNKT细胞免疫疗法的抗肿瘤潜力。这些结果有望揭示控制NB炎症启动和调节的新机制,并有助于确定用于开发NB和其他类型癌症有效免疫疗法的细胞和分子靶点。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.
  • DOI:
    10.1158/0008-5472.can-14-2946
  • 发表时间:
    2015-06-15
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Agarwal S;Lakoma A;Chen Z;Hicks J;Metelitsa LS;Kim ES;Shohet JM
  • 通讯作者:
    Shohet JM
C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes.
  • DOI:
    10.1002/cbic.201200374
  • 发表时间:
    2012-08-13
  • 期刊:
  • 影响因子:
    3.2
  • 作者:
    Liu, Zheng;Courtney, Amy N.;Metelitsa, Leonid S.;Bittman, Robert
  • 通讯作者:
    Bittman, Robert
Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
  • DOI:
    10.1002/ijc.24957
  • 发表时间:
    2010-06-01
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Xiong, Guosheng;Husseiny, Mohamed I.;Song, Liping;Erdreich-Epstein, Anat;Shackleford, Gregory M.;Seeger, Robert C.;Jaeckel, Daniela;Hensel, Michael;Metelitsa, Leonid S.
  • 通讯作者:
    Metelitsa, Leonid S.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leonid S Metelitsa其他文献

Leonid S Metelitsa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leonid S Metelitsa', 18)}}的其他基金

CAR NKT Cell Immunotherapy of Neuroblastoma
神经母细胞瘤的CAR NKT细胞免疫治疗
  • 批准号:
    10629276
  • 财政年份:
    2021
  • 资助金额:
    $ 24.96万
  • 项目类别:
CAR NKT Cell Immunotherapy of Neuroblastoma
神经母细胞瘤的CAR NKT细胞免疫治疗
  • 批准号:
    10427430
  • 财政年份:
    2021
  • 资助金额:
    $ 24.96万
  • 项目类别:
CAR NKT Cell Immunotherapy of Neuroblastoma
神经母细胞瘤的CAR NKT细胞免疫治疗
  • 批准号:
    10277506
  • 财政年份:
    2021
  • 资助金额:
    $ 24.96万
  • 项目类别:
Immunotherapy of B cell lymphoma with NK-T cells
NK-T 细胞对 B 细胞淋巴瘤的免疫治疗
  • 批准号:
    9354054
  • 财政年份:
    2007
  • 资助金额:
    $ 24.96万
  • 项目类别:
Project 1: Immunotherapy of B cell lymphoma with NKT cells
项目1:NKT细胞免疫治疗B细胞淋巴瘤
  • 批准号:
    10704633
  • 财政年份:
    2007
  • 资助金额:
    $ 24.96万
  • 项目类别:
Immunotherapy of B cell lymphoma with NK-T cells
NK-T 细胞对 B 细胞淋巴瘤的免疫治疗
  • 批准号:
    10247742
  • 财政年份:
    2007
  • 资助金额:
    $ 24.96万
  • 项目类别:
Immunotherapy of B cell lymphoma with NK-T cells
NK-T 细胞对 B 细胞淋巴瘤的免疫治疗
  • 批准号:
    10000870
  • 财政年份:
    2007
  • 资助金额:
    $ 24.96万
  • 项目类别:
Project 1: Immunotherapy of B cell lymphoma with NKT cells
项目1:NKT细胞免疫治疗B细胞淋巴瘤
  • 批准号:
    10495077
  • 财政年份:
    2007
  • 资助金额:
    $ 24.96万
  • 项目类别:
Localization and Function of NKT Cells in Neuroblastoma
神经母细胞瘤中 NKT 细胞的定位和功能
  • 批准号:
    8204860
  • 财政年份:
    2005
  • 资助金额:
    $ 24.96万
  • 项目类别:
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
神经母细胞瘤炎症的引发和调节
  • 批准号:
    9106698
  • 财政年份:
    2005
  • 资助金额:
    $ 24.96万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.96万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了